Skip to content

Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects

Comparison of Enteral Versus Parenteral Feeding in Healthy Human Subjects

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00856219
Acronym
Feeding
Enrollment
12
Registered
2009-03-05
Start date
2009-02-28
Completion date
2011-03-31
Last updated
2015-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Immune System

Brief summary

Literature suggests that route of feeding and/or certain nutrients may cause alterations in the body's immune cells. Immune cells help protect the body and fight infection/disease. Tube feeding (TF) is a method of delivering nutrition directly to the stomach/intestines via a small tube. The immune system may respond differently when receiving continuous TF as compared to receiving intermittent TF. Heart rate variability (HRV, the intervals between heartbeats) is a measurement of the nervous system's response to a stress/illness. The differences in immune cells and/or HRV may influence how the body reacts to complications such as infection.

Interventions

DIETARY_SUPPLEMENTEnteral Intermittent

Intermittent Tube Feedings

DIETARY_SUPPLEMENTParenteral Continuous

Parenteral Continuously for 72 hours

DIETARY_SUPPLEMENTEnteral Continuous

Continuous Tube Feeding for 72 hours

Sponsors

Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* General good health as demonstrated by medical history, physical& laboratory tests * Age between 18 and 40 years * Written informed consent prior to the performance of any study related procedures

Exclusion criteria

* History of cancer, rheumatoid arthritis, or immunological, renal, hepatic, endocrine, neurologic, heart disease or hypertension * Any medication taken in past 48 hrs (except birth control) * Recent history of alcohol or drug abuse * Unable to provide written informed consent * Exposure to any experimental agent or procedure within 30 days of study * Pregnant or breast-feeding

Design outcomes

Primary

MeasureTime frame
Route and type of feeding on Immune responseDay 1- Day 4

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026